Study Details
A Study of Enfortumab Vedotin in Japanese Subjects with Locally Advanced or Metastatic Urothelial Carcinoma
Clinicaltrials.gov ID
Astellas Study ID
7465-CL-0101
EudraCT ID
N/A
Condition
Bladder Cancer
Phase
Phase 1
Age
20 years - N/A
Sex
Female & Male
Product
ASG-22CE
Type
Interventional
Trial Dates
Apr 2017 - Feb 2019
Masking
None (Open Label)
Enrollment number
19
An Open-label, Randomized, Phase 1 Safety and Pharmacokinetic Study of Enfortumab Vedotin (ASG-22CE) in Japanese Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study of Enfortumab Vedotin in Japanese Subjects with Locally Advanced or Metastatic Urothelial Carcinoma? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site JP00001
Niigata, Japan
Site JP00002
Okayama, Japan
Site JP00008
Suita, Japan
Site JP00004
Chuo-ku, Japan
Site JP00005
Sendai, Japan
Site JP00007
Koto-ku, Japan
Site JP00003
Tsukuba, Japan
Site JP00006
Fukuoka, Japan